A new research method has elucidated cellular processes (involving mutated TP53 oncogene) that can convert a relatively benign myeloproliferative neoplasm into a threatening acute myeloid leukemia.
Findings from Oxford University in the UK—using the novel genetic sequencing tool: single cell multi omics—were reported at the ASH Plenary Session, by Oxford scientist Alba Rodriguez-Meira—winner of an ASH Abstract Achievement Award.
In this episode of the Audio Journal, Alba Rodriguez-Meira DPhil, PhD, from the Weatherall Institute of Molecular Medicine in Oxford discusses her award-winning research with Peter Goodwin.
Duration: 16:32 secs
ATLANTA, USA— In an inspiring presentation at the American Society of Hematology (ASH) 2021 Annual Meeting Plenary Session, Alba Rodriguez-Meira PhD, from the Weatherall Institute of Molecular Medicine at Oxford University in the UK, explained how her group’s (ASH Abstract Achievement Award-winning) research on the TP53 gene had made it possible to analyze the genome of a large number of individual cells from a relatively small sample of patients and healthy controls. https://ash.confex.com/ash/2021/webprogram/Paper150191.html
The study findings should provide predictive, prognostic and therapeutic tools that could improve otherwise dismal outcomes in subgroups of patients with hematologic malignancies.
“Our single cell multi omics analysis, coupled with in-vitro and in-vivo analysis, has allowed us to depict a model of TP53 -mediated transformation in myeloproliferative neoplasms in which inflammatory signaling leads to suppression of wild-type and MPN cells while giving a fitness advantage to TP53 [mutated] cells with leukemic stem-cell properties. From our study we hope to find this is applicable to many other cancer types,” said Rodriguez-Meira at the ASH session.
Single-cell multi omics analysis in a small patient cohort can theoretically be used to derive the gene signature that is highly relevant in much larger patient cohorts.
